Suv39h1 knockdown with shSUV-a accelerated the progression of leukemia with an average of 20.5-day survival in shSUV-a group vs. 23-day in scramble established in parallel with shSUV-a (Fig. 5f), and 26-day survival in shSUV-b group vs. 30.5-day in its parallel scramble (Fig. 5g). This evidence concerns the gene SUV39H1 and leukemia.